Royalty Pharma and Ascendis Pharma Announce Major Funding Agreement
Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S have unveiled an important collaboration valued at $150 million, aimed at supporting the U.S. launch of the groundbreaking treatment, Yorvipath. This funding agreement represents a crucial milestone, highlighting the dedication of both companies to advancing biopharmaceuticals, especially for conditions such as hypoparathyroidism.
Importance of the Partnership
Jan Mikkelsen, President and CEO of Ascendis Pharma, shared his excitement about the collaboration, stating, "We are pleased to again partner with Royalty Pharma, a leading funder of innovation across the biopharma industry. This transaction reflects the significant value of Yorvipath and our commitment to reduce our cost of capital while maintaining flexibility to support our global commercial capabilities.” His remarks underscore the critical role that financial partnerships play in successfully launching transformative medical therapies.
Agreement Details
According to the agreement, Ascendis will receive an upfront payment of $150 million in exchange for granting Royalty Pharma a 3% royalty on the U.S. net sales of Yorvipath. Importantly, these royalty payments will end once a revenue multiple of either 2.0x or 1.65x is achieved by the end of 2029.
Strategic Planning and Expert Guidance
The advisors for both companies were instrumental in structuring this deal. Evercore provided financial consulting services to Ascendis, while Latham & Watkins and Mazanti-Andersen served as legal advisors. Meanwhile, Royalty Pharma was supported by Goodwin Procter and Fenwick & West for its legal advisory needs. These professional collaborations helped shape an agreement that emphasizes mutual benefits and innovative funding solutions, which is a hallmark of Royalty Pharma's strategy.
About Royalty Pharma
Established in 1996, Royalty Pharma has earned a reputation as the largest buyer of biopharmaceutical royalties and a key supporter of innovation within the industry. With a diverse portfolio that includes over 35 commercial products, Royalty Pharma collaborates with innovators from academic and research institutions, biotech companies, and major pharmaceutical firms to advance vital therapies. Notable products in their portfolio include Vertex's Trikafta and Roche's Evrysdi, among others.
About Ascendis Pharma A/S
Ascendis Pharma is committed to developing therapies that significantly enhance patients’ lives. Utilizing its innovative TransCon technology platform, Ascendis aims to create potentially best-in-class therapies that address unmet medical needs. The company's dedication to patients and scientific advancement is clear, as it operates globally with a strong presence in both Europe and the United States.
Future Outlook
This collaboration not only strengthens Ascendis' financial resources for the launch of Yorvipath but also establishes a strategic milestone in the biopharmaceutical sector, marking the first approved treatment for adult hypoparathyroidism in the U.S. This represents a significant advancement in tackling the critical health challenges associated with this condition.
Frequently Asked Questions
What is Yorvipath?
Yorvipath is an FDA-approved treatment for hypoparathyroidism in adults, representing a significant advancement in managing this condition.
How much funding did Royalty Pharma provide?
Royalty Pharma has entered into a funding agreement worth $150 million to support the launch of Yorvipath.
What is the royalty percentage agreed upon?
Ascendis Pharma will pay Royalty Pharma a royalty of 3% on U.S. net sales of Yorvipath.
When will the royalty payments cease?
The royalty payments will stop once a multiple of 2.0x is reached, or 1.65x by December 31, 2029, if applicable.
Who were the advisors for this agreement?
Evercore acted as the financial advisor for Ascendis, while Goodwin Procter and Fenwick & West served as legal advisors for Royalty Pharma.
